Цефтаролин фозамил - цефалоспориновый антибиотик широкого спектра действия для лечения внебольничных пневмоний и осложнённых инфекций кожи и подкожной клетчатки

цефалоспорины, цефтаролин фозамил, внебольничные пневмонии, инфекции кожи и кодкожной клетчатки

1. Biek D., Critchley I.A., Riccobene T.A., Thye D.A. Ceftarolinefosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother November 2010; 65: 9-16.

2. Laudano J.B. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother April 2011; 66: 11-18.

3. Corey G.R., Wilcox M.H., Talbot G.H.,Thye D. et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother November 2010; 65: 41-51.

4. Wilcox M.H., Corey G.H., Talbot G.H., Thye D. et al. CANVAS 2: the second Phase III, randomized, double-blind study evaluating for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother November 2010; 65: 53-65.

5. Corrado M.L. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother November 2010; 65: 67-71.

6. File T.M., Jr, Low D.E., Eckburg P.B., Talbot G.H. et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother April 2011; 66: 19-32.

7. Low D.E., File T.M., Jr, Eckburg P.B., Talbot G.H. et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother April 2011; 66: 33-44.

8. Rank D.R., Friedland H.D., Laudano J.B. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother April 2011; 66: 53-59.

9. http://www.clinicaltrials.gov